Melanotic schwannoma: an 11-year case series

Khoo, Michael; Pressney, Ian; Hargunani, Rikin; Tirabosco, Roberto

doi:10.1007/s00256-015-2256-8

Cited by 37 publications

(26 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ages of those afflicted vary between 10 and 84 years (7,9), although the peak incidence occurs with patients in their fourth decade (7). There have been fewer than 200 cases of PNST reported since it was first described in 1932 (10,11), with approximately 40 reported malignancies as of 2014 (12). To date, there have been no published cases of MPNST originating from the parotid gland.…”

Section: Discussionmentioning

confidence: 99%

Rexin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report

Kim

Federman

Gordon

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Soft tissue sarcoma is a rare neoplasm of mesenchymal origin, accounting for only ~1% of all adult cancers and consisting of 75 histological subtypes. In the present report, the unique case of a 14 year-old female with metastatic malignant peripheral nerve sheath tumor (formerly, malignant melanotic schwannoma) of the parotid gland, who experienced a durable response and sustained tumor control with Rexin-G®, a tumor-targeted retroviral expression vector encoding an anti-cyclin G1 construct, is described. Post-parotidectomy, and prior to the administration of Rexin-G®, the patient received various chemotherapy regimens, including doxorubicin, ifosfamide, temozolomide, sorafenib, and an immunological therapy with interleukin-2, which only resulted in the further progression of lung metastases. The patient subsequently participated in a Phase 1/2 gene therapy study, during which she received intravenous Rexin-G® as monotherapy for two years with minimal drug-associated adverse events. Currently, the patient has no evidence of active disease 9 years after commencing the Rexin-G® treatment, and with no additional anti-cancer therapy. In conclusion, Rexin-G® may be a viable therapeutic option for malignant peripheral nerve sheath tumors, and should be further investigated in prospective histology-specific clinical trials for this type, and possibly other types, of chemotherapy-resistant sarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Rexin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report

Kim

Federman

Gordon

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…The gray-brown pigment occasionally seen in conventional schwannoma represents lipofuscin opposed to true melanin [1]. Although nerve roots and the paraspinal sympathetic chain are the most frequent locations of melantoic schwannomas, they may present at various anatomic locations [1,2]. However, their presence in the foot is extremely rare with very few cases published in the literature.…”

Section: Discussionmentioning

confidence: 99%

“…Schwannomas are solitary, slow-growing, and encapsulated benign soft tissue neoplasms composed of differentiated neoplastic Schwann cells [1]. These soft tissue tumors are thought to arise sporadically [2]. A melanotic or melanocytic, schwannoma is a rare variant of a schwannoma that typically involves spinal nerve roots [1,2].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pedal Melanotic Schwannoma: A Case Report

Woodley¹,

Micciche²,

Klush³

2017

Tumor Res

View full text Add to dashboard Cite

Background: Melanotic or melanocytic schwannoma is a rare variant of a schwannoma. It is composed of melanin-producing cells with the ultra-structural features of Schwann cells along with the cytoplasmic deposition of melanin. The occurrence of a melanotic schwannoma is particularly rare in the foot. Regardless of anatomic location, they are considered to be benign soft tissue masses. Case description:A 78 year old Caucasian female presented to a physician's office with complaints of onchyomycosis. Incidentally, it was noted that the patient had large a mass on the plantar aspect of her right foot. She denied any complaints regarding the mass. The mass had been present for approximately one year and was slowly increasing in size. An MRI revealed a heterogeneous macrolobulated mass measuring 3.0 × 8.3 × 5.3 cm and could not rule out malignancy. A surgical biopsy was then performed. Conclusion:Melanotic schwannomas have the ability to mirror malignancy, both on physical exam and on advanced imaging modalities. A biopsy procedure provides a definitive diagnosis and contributes to the definitive treatment plan.

show abstract

“…14 Melanocytic schwannoma consisting of cells with ultrastructure and the immunophenotype of Schwann cells contains melanosomes, reactivity to melanoma markers, heavy melanin deposition, presence of psammoma bodies, nuclear pleomorphism and low mitotic rate. 15,16 Hyperchromasia and macronuclei are common cytological atypia, unlike the reticulin pattern that is generally poor in this subtype. 2 Melanotic Schwannoma is a rare primary tumor, predominating in spinal and paraspinal nerves, with a global prevalence of less than 1% of primary PNSTs.…”

Section: Histopathologymentioning

confidence: 99%

Peripheral Nerve Schwannomas: A Literature Review

et al. 2019

View full text Add to dashboard Cite

Introduction Schwannomas are benign tumors originating from the cells, which wrap around axons that are usually encapsulated and solitary. These tumors usually lead to little or no symptomatology. They are usually the most common peripheral nerve tumors in adults, with their highest incidence between the third and fifth decades of life. Objective To perform a review about schwannoma of the peripheral nerves, presenting its definition, epidemiology, diagnosis, symptomatology and treatment. Methodology This is a descriptive work, based on a review of articles available in the PubMed database with the descriptors schwannoma and peripheral nerves. Results and Discussion Only papers published between 1981 and 2019, describing studies in humans, and that were available as full articles were selected. A total of 391 articles were included; after reading the titles, we noted that 67 articles fit the topic of the present study. Among the articles selected for reading, 33 fit the objectives of the present work, and were considered for the writing of the present article. Conclusion Schwannomas are benign myelin sheath tumors that develop with local symptomatology or asymptomatic and present a good surgical prognosis with generally reduced rates of surgical complications.

show abstract

Melanotic schwannoma: an 11-year case series

Cited by 37 publications

References 14 publications

Rexin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report

Rexin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report

Pedal Melanotic Schwannoma: A Case Report

Peripheral Nerve Schwannomas: A Literature Review

Contact Info

Product

Resources

About